Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Ginkgo Bioworks Holdings (DNA) through the VizualStocks API.
Operating income or loss from Ginkgo's cell-engineering tools and services, including automated lab systems, biological data packages and R&D programs that design organisms or cell lines for customers.
cellEngineeringOperatingIncomeRevenue from Ginkgo's biological R&D tools and solutions, including automated lab design and support, Datapoints data packages and cell-programming services that produce engineered strains or cell lines. Contracts can include service fees, technical milestones, licenses and potential downstream royalties.
cellEngineeringRevenueCorporate operating costs or income that Ginkgo does not allocate to Cell Engineering or Biosecurity, including central public-company and shared functions. The line is generally a loss and reconciles segment results to the consolidated total.
corporateOperatingIncomeOperating income or expense needed to reconcile Ginkgo's separately reported Cell Engineering, Biosecurity and corporate components to consolidated operating results. It is not revenue or profit from another customer-facing business.
otherOperatingIncomeReconciliationCustomer cell-engineering programs that generated recognized revenue during the reporting period. A program is a technical development plan for Ginkgo to solve a customer's biological R&D objective, not a standalone software subscription.
revenueGeneratingProgramsOperating income or loss from Ginkgo's Biosecurity business, which provides governments and other customers with pathogen sample collection, sequencing, biomonitoring and threat-analysis services through Canopy and Horizon.
biosecurityOperatingIncomeRevenue from Ginkgo's Canopy biomonitoring and Horizon threat-analytics offerings, including sample collection, transport, lab sequencing, web-based results and bioinformatics reporting. Government agencies are the primary customers.
biosecurityServiceRevenueCumulative number of unique customer cell-engineering programs Ginkgo had started through period end, excluding proof-of-concept and exploratory projects. Ginkgo stopped using this legacy KPI after the third quarter of 2024 as its service offerings and commercial model changed.
cumulativeProgramsUnique customer cell-engineering programs for which Ginkgo performed R&D services during the period. Ginkgo discontinued this legacy KPI after the third quarter of 2024 following its restructuring and expansion into newer service formats.
currentActiveProgramsUnique customer cell-engineering programs that began during the period under a technical development plan, excluding proof-of-concept and exploratory work. Ginkgo stopped relying on this legacy KPI after the third quarter of 2024 as its contract types broadened.
newPrograms